Mortality is higher in developing countries, doing special mention to the black populations. Prostate cancer is the second most common cancer among men, after skin cancer1 and the fifth-leading cause of death, accounting for 6.6% of all cancer deaths, worldwide. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC.Ĭonclusions: Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty. Therefore, incremental costs per QALY were €27 606. Results: Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. Unit costs were retrieved from Spanish databases and published sources. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Purpose: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain.ĭesign and methods: A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |